Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study

• Egile Nagusiak: Pierantonio Menna (Egilea), Francesco Marchesi (Egilea), Chiara Cattaneo (Egilea), Anna Candoni (Egilea), Mario Delia (Egilea), Gianpaolo Nadali (Egilea), Alessandra Vatteroni (Egilea), Crescenza Pasciolla (Egilea), Salvatore Perrone (Egilea), Luisa Verga (Egilea), Daniele Armiento (Egilea), Maria Ilaria Del Principe (Egilea), Nicola S. Fracchiolla (Egilea), Emanuela Salvatorelli (Egilea), Santina Lupisella (Egilea), Irene Terrenato (Egilea), Alessandro Busca (Egilea), Giorgio Minotti (Egilea), Livio Pagano (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2023-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Midostaurin is used in combination with chemotherapy to treat patients with newly diagnosed FLT3‐mutated acute myeloid leukemia. Chemotherapy‐induced neutropenia exposes these patients to a significant risk of invasive fungal infections (IFIs). International guidelines recommend primary ant...